# US 2003/0211579 A1 · Methods for increasing polypeptide production

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0211579 A1
- Document ID: US20030211579A1
- Status: Published application
- Kind: A1
- Application number: 10/400,334
- Filed: 2003-03-27
- Published: 2003-11-13
- Earliest claimed: 2002-03-27
- Assignees: Immunex Corporation
- Inventors: Kirk P. Van Ness; Michael T. Trentalange; Bradley D. Dell; Jeffrey T. McGrew
- Web page: https://patentgrep.com/patent/US20030211579A1

## CPC

- C12P 21/02: having a known sequence of two or more amino acids, e.g. glutathione
- C12N 5/0018: {Culture media for cell or tissue culture (media for specific animal cell type C12N5/06)}
- C12N 15/67: General methods for enhancing the expression
- C07K 2319/00: Fusion polypeptide
- C12N 2500/36: Lipids
- C12N 2501/01: Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
- C12N 2510/02: Cells for production
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention provides methods of increasing the production of polypeptides, optionally recombinant polypeptides, from mammalian cells using xanthine derivatives or hybrid polar compounds and cultures containing the same. Combinations of inducers including a hybrid polar compound and/or a xanthine derivative and/or an alkanoic acid can also be used, optionally at temperatures less than 37° C.

## Claims

### Claim 1

A method for producing a polypeptide comprising:
culturing a mammalian cell line in a growth phase followed by a production phase, wherein the production phase occurs at a temperature of less than 37° C.; and
adding to the culture medium during the production phase a xanthine derivative;
wherein the addition of the xanthine derivative increases production of the polypeptide; and
wherein the mammalian cell line is selected from the group consisting of a mammalian cell line that has been genetically engineered to produce the polypeptide and a hybridoma cell line that produces an antibody.

### Claim 2 (depends on 1)

The method of claim 1,
wherein the mammalian cell line has been transformed with a recombinant vector encoding the polypeptide, and
wherein the recombinant vector comprises a CMV promoter.

### Claim 3 (depends on 1)

The method of claim 1, wherein the xanthine derivative is caffeine at a concentration from about 0.01 millimolar to about 3.0 millimolar.

### Claim 4 (depends on 1)

The method of claim 1, wherein the polypeptide is a recombinant fusion polypeptide.

### Claim 5 (depends on 1)

The method of claim 1, wherein the polypeptide is a human or humanized antibody.

### Claim 6 (depends on 1)

The method of claim 1, wherein the production phase occurs at a temperature from about 29° C. to about 36° C.

### Claim 7 (depends on 1)

The method of claim 1, wherein the concentration of each xanthine derivative added to the culture is from about 0.001 millimolar to about 3 millimolar.

### Claim 8 (depends on 1)

The method of claim 1, wherein the xanthine derivative is selected from the group consisting of caffeine, 3-isobutyl-1-methylxanthine, theobromine, and pentoxyphylline.

### Claim 9 (depends on 1)

The method of claim 1, wherein at least two different xanthine derivatives are added.

### Claim 10 (depends on 9)

The method of claim 9, wherein the two different xanthine derivatives are caffeine and 3-isobutyl-1-methylxanthine.

### Claim 11 (depends on 1)

The method of claim 1, wherein the mammalian cell line is a CHO cell line.

### Claim 12 (depends on 11)

The method of claim 11, wherein the CHO cell line is exposed to the xanthine derivative or derivatives for at least about 5 days.

### Claim 13 (depends on 1)

The method of claim 1, wherein the medium used during the production phase is serum free.

### Claim 14 (depends on 1)

The method of claim 1, further comprising collecting the polypeptide from the medium.

### Claim 15 (depends on 14)

The method of claim 14, further comprising formulating the polypeptide.

### Claim 16 (depends on 1)

The method of claim 1, further comprising multiple additions of the xanthine derivative.

### Claim 17 (depends on 1)

The method of claim 1, wherein the medium further comprises a hybrid polar compound.

### Claim 18 (depends on 17)

The method of claim 17, wherein the medium further comprises an alkanoic acid.

### Claim 19 (depends on 1)

The method of claim 1, wherein the medium further comprises an alkanoic acid.

### Claim 20 (depends on 17)

The method of claim 17, wherein the hybrid polar compound is hexamethylene bisacetamide and the xanthine derivative is caffeine.

### Claim 21 (depends on 20)

The method of claim 20,
wherein the medium further comprises a salt of butyric acid at a concentration from about 0.1 millimolar to about 2 millimolar,
wherein hexamethylene bisacetamide is at a concentration from about 0.1 millimolar to about 5 millimolar, and
wherein caffeine is at a concentration from about 0.01 millimolar to about 5 millimolar.

### Claim 22 (depends on 17)

The method of claim 17, wherein the mammalian cell line is cultured at a temperature from about 29° C. to about 36° C.

### Claim 23 (depends on 22)

The method of claim 22, wherein the mammalian cell line is cultured at a temperature from about 30° C. to about 33° C.

### Claim 24 (depends on 22)

The method of claim 22,
wherein the mammalian cell line is cultured in the growth phase at a first temperature from about 35° C. to about 38° C. before it is shifted to the production phase at a second temperature from about 29° C. to about 36° C. and
wherein the hybrid polar compound and the xanthine are added after the shift from the first temperature to the second temperature.

### Claim 25 (depends on 18)

The method of claim 18, wherein the mammalian cell line is cultured at a temperature from about 29° C. to about 36° C.

### Claim 26

A method for producing a recombinant polypeptide comprising:
culturing a CHO cell line that has been genetically engineered to produce the recombinant polypeptide; and
adding to the culture medium at least one xanthine derivative selected from the group consisting of theobromine and caffeine,
wherein the addition of the xanthine derivative increases the production of the recombinant polypeptide.

### Claim 27 (depends on 26)

The method of claim 26,
wherein the CHO cell line has been transformed with a recombinant vector encoding the recombinant polypeptide and
wherein the recombinant vector comprises a CMV promoter.

### Claim 28 (depends on 26)

The method of claim 26, wherein the recombinant polypeptide is a fusion polypeptide.

### Claim 29 (depends on 26)

The method of claim 26, wherein the recombinant polypeptide is a human or humanized antibody.

### Claim 30 (depends on 26)

The method of claim 26, wherein the concentration of each xanthine derivative added to the culture medium is from about 0.001 millimolar to about 3 millimolar.

### Claim 31 (depends on 26)

The method of claim 26, wherein the xanthine derivative is caffeine.

### Claim 32 (depends on 26)

The method of claim 26, further comprising collecting the recombinant polypeptide from the medium.

### Claim 33 (depends on 32)

The method of claim 32, further comprising formulating the recombinant polypeptide.

### Claim 34 (depends on 26)

The method of claim 26, further comprising multiple additions of the xanthine derivative.

### Claim 35 (depends on 26)

The method of claim 26, wherein the CHO cell line is cultured at a temperature from about 29° C. to about 36° C.

### Claim 36 (depends on 35)

The method of claim 35, wherein the CHO cell line is cultured at a temperature from about 30° C. to about 33° C.

### Claim 37 (depends on 35)

The method of claim 35,
wherein the CHO cell line is cultured at a first temperature from about 35° C. to about 38° C. before it is shifted to a second temperature from about 29° C. to about 36° C. and
wherein the xanthine derivative is added after the shift from the first temperature to the second temperature.

### Claim 38

A culture comprising a CHO cell genetically engineered to produce a polypeptide, a production medium, and a xanthine derivative selected from the group consisting of caffeine, theobromine, and pentoxyphylline.

### Claim 39 (depends on 38)

The culture of claim 38, wherein the concentration of each xanthine derivative present is from about 0.01 millimolar to about 3 millimolar.

### Claim 40 (depends on 38)

The culture of claim 38, wherein the production medium is serum-free.

### Claim 41 (depends on 38)

The culture of claim 38, wherein the culture comprises at least two xanthine derivatives.

### Claim 42

A method for producing a recombinant polypeptide comprising
culturing a mammalian cell line at a temperature from about 29° C. to about 36° C. and
adding a hybrid polar compound to the culture medium,
wherein the mammalian cell line has been genetically engineered to produce the recombinant polypeptide and
wherein the addition of the hybrid polar compound increases the production of the recombinant polypeptide.

### Claim 43 (depends on 42)

The method of claim 42, wherein the hybrid polar compound is hexamethylene bisacetamide at a concentration from about 0.1 millimolar to about 20 millimolar.

### Claim 44 (depends on 42)

The method of claim 42,
wherein the mammalian cell line is cultured at a first temperature from about 35° C. to about 38° C. before it is shifted to a second temperature from about 29° C. to about 36° C. and
wherein the hybrid polar compound is added is added after the shift from the first temperature to the second temperature.

### Claim 45 (depends on 42)

The method of claim 42, wherein the medium further comprises an alkanoic acid at a concentration from about 0.05 millimolar to about 10 millimolar.

### Claim 46 (depends on 43)

The method of claim 43, wherein the hexamethylene bisacetamide in the medium is present at a concentration from about 0.1 millimolar to about 5 millimolar.

### Claim 47 (depends on 42)

The method of claim 42, wherein the mammalian cell line is cultured at a temperature from about 30° C. to about 33° C.

### Claim 48 (depends on 45)

The method of claim 45, wherein
the alkanoic acid is a salt of butyric acid, and
the concentration of the salt of butyric acid is from about 0.1 millimolar to about 2 millimolar.

### Claim 49 (depends on 45)

The method of claim 45, wherein
the hybrid polar compound is hexamethylene bisacetamide at a concentration from about 0.1 millimolar to about 5 millimolar, and
the alkanoic acid is a salt of butyric acid at a concentration from about 0.1 millimolar to about 2 millimolar.

### Claim 50 (depends on 42)

The method of claim 42, wherein the medium is serum free.

### Claim 51 (depends on 42)

The method of claim 42, wherein the medium further comprises a xanthine derivative.

### Claim 52 (depends on 51)

The method of claim 51, wherein the xanthine derivative is caffeine.

### Claim 53 (depends on 51)

The method of claim 51, wherein the medium further comprises a salt of butyric acid.

### Claim 54 (depends on 53)

The method of claim 53, wherein the xanthine derivative is present at a concentration from about 0.01 millimolar to about 3 millimolar and the salt of butyric acid is present at a concentration from about 0.1 millimolar to about 2 millimolar.

### Claim 55 (depends on 42)

The method of claim 42, wherein the recombinant polypeptide is a secreted polypeptide.

### Claim 56 (depends on 55)

The method of claim 55, further comprising recovering the recombinant polypeptide from the medium.

### Claim 57 (depends on 42)

The method of claim 42, wherein the mammalian cell line is a CHO cell line.

### Claim 58

A method for producing a polypeptide comprising
culturing a mammalian cell line that can express the polypeptide in a growth phase at a first temperature from about 35° C. to about 38° C., and then
culturing the mammalian cell line in a production phase at a second temperature from about 30° C. to 34° C. in a medium comprising a hybrid polar compound.

### Claim 59 (depends on 58)

The method of claim 58, wherein the polypeptide is a recombinant polypeptide or an antibody.

### Claim 60 (depends on 58)

The method of claim 58, wherein the hybrid polar compound is hexamethylene bisacetamide.

### Claim 61 (depends on 58)

The method of claim 58, wherein the medium further comprises an alkanoic acid.

### Claim 62 (depends on 61)

The method of claim 61, wherein the hybrid polar compound is hexamethylene bisacetamide and the alkanoic acid is a salt of butyric acid.

### Claim 63 (depends on 58)

The method of claim 58, wherein the medium is serum free.

### Claim 64 (depends on 58)

The method of claim 58, wherein the hybrid polar compound is added after the shift from the first temperature to the second temperature.

### Claim 65 (depends on 58)

The method of claim 58, wherein
the medium further comprises a xanthine derivative at a concentration from about 0.001 millimolar to about 5.0 millimolar and an alkanoic acid at a concentration from about 0.05 millimolar to about 10.0 millimolar and
the hybrid polar compound is hexamethylene bisacetamide at a concentration from about 0.1 millimolar to about 5 millimolar.

### Claim 66 (depends on 58)

The method of claim 58, wherein the mammalian cell line is a hybridoma cell line or a CHO cell line.

### Claim 67

A method for producing a polypeptide comprising culturing mammalian cells that can produce the polypeptide in a medium comprising between about 0.1 millimolar and about 5 millimolar hexamethylene bisacetamide, from about 0.1 millimolar to about 2 millimolar butyric acid, and from about 0.1 millimolar to about 4 millimolar caffeine at a temperature from about 30° C. to about 36° C.

### Claim 68 (depends on 67)

The method of claim 67, wherein the polypeptide is selected from the group consisting of RANK:Fc, type II interleukin-1 receptor, TNFR:Fc, CD40 ligand, TRAIL, flt3-ligand, IL4 receptor, G-CSF, erythropoietin, an antibody, and substantially similar polypeptides.

### Claim 69

A cell culture comprising a CHO cell line that has been genetically engineered to produce a polypeptide and a production medium comprising hexamethylene bisacetamide, wherein the culture is incubated at a temperature from about 30° C. to 36° C. for at least about 5 days.
